Nuclear Medicine and Biology
Volume 35, Issue 7 , Pages 741-746, October 2008

A convenient solution-phase method for the preparation of meta-iodobenzylguanidine in high effective specific activity

Departments of Chemistry and Medical Physics & Applied Radiation Sciences, McMaster University, Hamilton, ON, Canada, L8S 4M1

Received 17 April 2008; received in revised form 14 July 2008; accepted 24 July 2008.

Abstract 

Introduction

There is a need for new methods of producing receptor-targeted molecular radioimaging and radiotherapy agents in high effective specific activity. This is particularly true for targets that are expressed in relatively low concentrations.

Methods

A highly fluorinated (fluorous) tin precursor of meta-iodobenzylguanidine (MIBG) was prepared, such that upon labeling, the desired product was formed with concomitant release of the fluorous group. The desired product was then readily separated from the starting material and fluorous by-products by chemoselective filtration using a fluorous solid-phase extraction cartridge.

Results

High purity [125I]- and [123I]MIBG were produced in 81±3% and 80% radiochemical yield respectively in less than 20 min without high-performance liquid chromatography (HPLC) purification. The purified product contained less than 1 ppm tin as determined by inductively coupled plasma-mass spectrometry (ICP-MS).

Conclusions

A convenient, solution-phase method to produce radioiodinated MIBG in high effective specific activity without employing preparative HPLC was developed. Using the reported approach, a kit for the production of 123I- and 125I-MIBG is feasible and is currently being developed.

Keywords: Meta-iodobenzylguanidine, Fluorous labelling strategy, Specific activity, Destannylation

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0969-8051(08)00175-3

doi:10.1016/j.nucmedbio.2008.07.006

Nuclear Medicine and Biology
Volume 35, Issue 7 , Pages 741-746, October 2008